A real-world study conducted in Spain on patients with inflammatory bowel disease (IBD) receiving either the adalimumab originator or biosimilar MSB11022 (Idacio; Fresenius Kabi) found “no...
When you live with a chronic disease, it means dealing with an ever-present stream of stressors that other people don’t even think about, like regular doctor’s...